Adoptive cell therapy (ACT) is rapidly migrating from bench to clinical therapy for hematological malignancies. Recently, a new subtype of memory T cells, stem cell memory T (TSCM) cells, was shown to be one of the most favorable subsets for ACT. TSCM has high self-renewal capacity and is associated with superior T cell engraftment, persistence, and antitumor immunity. In this review, we focused on the characteristics of antigen-specific TSCM cells and discussed their potential for immunotherapy targeting hematological malignancies.
CITATION STYLE
Xu, L., Zhang, Y., Luo, G., & Li, Y. (2015, October 14). The roles of stem cell memory T cells in hematological malignancies. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-015-0214-5
Mendeley helps you to discover research relevant for your work.